BeOne
NEWS
Biotech and pharma companies from across Europe and Asia share company and pipeline updates.
The companies will combine their research expertise to develop BGB-3245, an investigational, oral, selective small molecule inhibitor of monomer and dimer forms of activating B-RAF mutations including V600 BRAF mutations, non-V600 B-RAF mutations, and RAF fusions.
Chinese companies that gain toeholds in the U.S. are poaching executives from U.S. companies who have significant clinical and regulatory experience.
BeiGene, Ltd. today announced the acceptance by the China National Medical Products Administration (NMPA) of a new drug application (NDA) for zanubrutinib, an investigational Bruton’s tyrosine kinase (BTK) inhibitor
China’s Innovent Biologics reportedly is continuing with its plans to raise $423 million in its Hong Kong IPO. If so, it would be the biggest biotech IPO out of Hong Kong this year.
Brii Biosciences is one of many China-based companies that are heavily investing in U.S. biotech and pharmaceutical companies to support the development of programs that could come back to China for approval.
China’s Hillhouse Capital Group, an equity investment firm, has a new fund, Hillhouse Fund IV, with $10.6 billion ready to invest.
BeiGene to build late-stage clinical and commercial production capacity for cancer monoclonal antibodies with GE Healthcare’s KUBio, the prefabricated biopharma facility based on single-use technologies
Without a doubt China has become one of the most important markets for pharma companies, given the vast patient population and the rising cancer rates. And it seems that western pharmaceutical companies are making greater inroads there.
JOBS
IN THE PRESS